General Discussions

Avastin Alarm

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone. The review, which was published in the Journal of the American Medical Association, included 16 trials with 10,217 patients. Overall, treatment-related death occurred in 2.5% of the Avastin population. The authors maintain the potential survival benefits may still outweigh the fatality risk when evaluating treatment options. Avastin is FDA-approved for the treatment of colon, kidney, brain, and lung cancers; however, the agency is in the process of revoking its breast cancer indication.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.